, which considers the global health responsibilities of pharmaceutical companies, and makes the case for a new kind of ethical investment in public health. Her recent pieces draw on ideas that she first laid out in the book, written long before the coronavirus pandemic. “The idea is, can we better align research and development with health impact rather than sales volume?” she asked. The human right to health While tuberculosis, AIDS and malaria remain stark realities in the developing world, the medications that treat them are scarce, costly and increasingly obsolete as resistance rates rise. Coronavirus also has a harsh outlook in poorer nations, where ventilators and hospital critical-care facilities are in short supply.